ASS1 and hepatocellular carcinoma: Our results showed that circRAPGEF1‐overexpressing HCC cells displayed reduced sensitivity to sorafenib compared with control cells, whereas ASS1 overexpression partially restored sorafenib sensitivity (Figure 8A).